February 11, 2014 - Saluggia (VC) - DiaSorin (FTSE Mid Cap:DIA) is pleased to announce that it launched the LIAISON Rotavirus test for the qualitative detection of Rotavirus in stool specimens, available in the market outside the US and UK only.

The new LIAISON Rotavirus is the fifth test launched on the LIAISON Stool menu, in addition to the other tests already on the market (C. difficile Toxin AB, C. Difficile GDH, H. pylori, EHEC) since 2013. 

DiaSorin's LIAISON solution aims at improving the way Rotavirus test is currently performed; differently from the past, this test allows to obtain rapid results on a large volume of samples. In fact one key element of the test is to be able to give a result in the shortest time possible in order to isolate and treat the infection in the best way.

Rotavirus is the most common cause of severe diarrhea among infants and children throughout the world and causes the death of about 500,000 of them worldwide annually.  Nearly every child in the world has been infected with rotavirus at least once by the age of five. The virus is transmitted by the faecal-oral route and it infects and damages the cells that line the small intestine and causes gastroenteritis.

 According to last estimates the Rotavirus test is performed everywhere in the world and therefore the new DiaSorin test will be able to address an important market worldwide. Today Europe alone counts around 6 million tests per year with a market value that is estimated to be over €10 Million.

distributed by